These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37386461)

  • 21. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
    Arici M; Altun B; Araz M; Atmaca A; Demir T; Ecder T; Guz G; Gogas Yavuz D; Yildiz A; Yilmaz T
    Front Med (Lausanne); 2024; 11():1384454. PubMed ID: 38947237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
    Vaduganathan M; Claggett BL; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Desai AS; Jhund PS; Viswanathan P; Bomfim Wirtz A; Schloemer P; Lay-Flurrie J; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2024 Jun; 26(6):1324-1333. PubMed ID: 38742248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
    Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
    Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
    Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
    Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
    Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
    Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A;
    Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
    Lerma EV; Wilson DJ
    Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
    Doggrell SA
    Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
    [No Abstract]   [Full Text] [Related]  

  • 37. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
    Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.
    Piccirillo F; Liporace P; Nusca A; Nafisio V; Corlianò A; Magarò F; Antonelli Incalzi R; Ussia GP; Grigioni F
    J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.